Clinicopathological analysis of XXXX and literature review.

@entity1 @entity3975 @entity5 @entity2347 @entity957 @entity189 @entity3981 @entity3
@entity5 are rare and exhibit a broad spectrum of phenotypic heterogeneity. The objective of this study was to investigate prognostic factors in @entity1 with @entity189 and review the results in light of other reports. We retrospectively reviewed 40 @entity1 with primary @entity189 who were diagnosed and treated at our institution between 1991 and 2014. Of the 40 @entity5 , 19 (47.5%) were @entity3975 , 11 (27.5%) were @entity2347 , 7 (17.5%) were @entity3981 , 2 (5.0%) were @entity189 and 1 (2.5%) was a @entity957 . Clinically positive lymph nodes were present in 4 @entity1 (10.0%). As regards clinical stage, 15 cases (37.5%) were stage I, 13 (32.5%) were stage II, 1 (2.5%) was stage III and 11 (27.5%) were stage IVA. The majority of the @entity1 (97.5%) were treated with surgery, of whom 25 (62.5%) received surgery alone and 14 (35.0%) underwent surgery in combination with chemotherapy or chemotherapy and radiotherapy. The median follow-up time for all the @entity1 was 48 months. The disease-specific survival rate at 5 years was 87.1%. We identified a significant correlation between poor survival rate and histological grade (intermediate/high), @entity5 size (T3/T4), lymph node @entity3 (node-positive) and clinical stage (III/IV) using the Kaplan-Meier method (P<0.05 for each). In addition, the Cox proportional hazards regression analysis confirmed that lymph node @entity3 and @entity5 size were independent prognostic factors for disease-specific survival (hazard ratio = 18.7 and 15.1, respectively; P=0.023 and 0.037, respectively). Furthermore, @entity5 size was found to be a predictive factor regarding recurrence in the multivariate logistic regression analysis (odds ratio = 8.35; P=0.025). Our results suggest that lymph node @entity3 and @entity5 size are significant prognostic factors for @entity1 with @entity189 .
